Skip to main content
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Article

A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent towards acute myeloid leukemia

Ronja Bjørnstad, Reidun Aesoy, Øystein Bruserud, Annette K. Brenner, Francis Giraud, Tara Helen Dowling, Gro Gausdal, Pascale Moreau, Stein Ove Døskeland, Fabrice Anizon and Lars Herfindal
Ronja Bjørnstad
Centre for Pharmacy, Department of Clinical Science, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reidun Aesoy
Centre for Pharmacy, Department of Clinical Science, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Reidun Aesoy
Øystein Bruserud
Department of Clinical Science, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette K. Brenner
Department of Clinical Science, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis Giraud
CNRS, Institut de Chimie de Clermont-Ferrand, Université Clermont Auvergne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara Helen Dowling
Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gro Gausdal
BerGenBio ASA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascale Moreau
CNRS, Institut de Chimie de Clermont-Ferrand, Université Clermont Auvergne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pascale Moreau
Stein Ove Døskeland
Department of Biomedicine, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrice Anizon
CNRS, Institut de Chimie de Clermont-Ferrand, Université Clermont Auvergne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabrice Anizon
Lars Herfindal
Centre for Pharmacy, Department of Clinical Science, University of Bergen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lars.herfindal@uib.no
DOI: 10.1158/1535-7163.MCT-17-1234
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

More than 40 years ago, the present standard induction therapy for acute myeloid leukemia (AML) was developed. This consists of the metabolic inhibitor cytarabine (AraC) and the cytostatic topoisomerase 2 inhibitor daunorubucin (DNR). In light of the high chance for relapse, as well as the large heterogeneity, novel therapies are needed to improve patient outcome. We have tested the anti-AML activity of 15 novel compounds based on the scaffolds pyrrolo[2,3-a]carbazole-3-carbaldehyde, pyrazolo[3,4-c]carbazole, pyrazolo[4,3-a]phenanthridine or pyrrolo[2,3-g] indazole. The compounds were inhibitors of Pim-kinases, but could also have inhibitory activity against other protein kinases. Ser/Thr kinases like the Pim-kinases have been identified as potential drug targets for AML therapy. The compound VS-II-173 induced AML cell death with EC50 below 5 μM, and was ten times less potent against non-malignant cells. It perturbed Pim kinase mediated AML cell signaling, such as attenuation of Stat5 or MDM2 phosphorylation, and synergized with DNR to induce AML cell death. VS-II-173 induced cell death also in AML patient blasts, including blast carrying high-risk FLT3-ITD mutation. Mutation of nucleophosmin-1 was associated with good response to VS-II-173. In conclusion new scaffolds for potential AML drugs have been explored. The selective activity towards patient AML blasts and AML cell lines of the pyrazolo-analogue VS-II-173 make it a promising drug candidate to be further tested in pre-clinical animal models for AML.

  • Received December 13, 2017.
  • Revision received May 5, 2018.
  • Accepted January 14, 2019.
  • Copyright ©2019, American Association for Cancer Research.
PreviousNext
Back to top

Published OnlineFirst January 24, 2019
doi: 10.1158/1535-7163.MCT-17-1234

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent towards acute myeloid leukemia
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent towards acute myeloid leukemia
Ronja Bjørnstad, Reidun Aesoy, Øystein Bruserud, Annette K. Brenner, Francis Giraud, Tara Helen Dowling, Gro Gausdal, Pascale Moreau, Stein Ove Døskeland, Fabrice Anizon and Lars Herfindal
Mol Cancer Ther January 24 2019 DOI: 10.1158/1535-7163.MCT-17-1234

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent towards acute myeloid leukemia
Ronja Bjørnstad, Reidun Aesoy, Øystein Bruserud, Annette K. Brenner, Francis Giraud, Tara Helen Dowling, Gro Gausdal, Pascale Moreau, Stein Ove Døskeland, Fabrice Anizon and Lars Herfindal
Mol Cancer Ther January 24 2019 DOI: 10.1158/1535-7163.MCT-17-1234
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cyr61 promotes gemcitabine resistance in PDAC cells
  • β-Arrestins regulate chemotherapy response in bladder cancer
  • TAS0728 as a covalent-binding HER2 selective inhibitor
Show more Research Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright 2016 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement